{"id":217059,"date":"2019-07-19T08:30:51","date_gmt":"2019-07-19T03:00:51","guid":{"rendered":"https:\/\/www.scconline.com\/blog\/?p=217059"},"modified":"2019-07-25T15:58:07","modified_gmt":"2019-07-25T10:28:07","slug":"del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up","status":"publish","type":"post","link":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/","title":{"rendered":"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0"},"content":{"rendered":"<p style=\"text-align: justify;\"><b>Delhi High Court: <\/b>The Division Bench of Dr S. Muralidhar and Talwant Singh, JJ. allowed the appeal filed by Natco Pharma Ltd. and quashed the order of the Single Judge restraining Natco Pharma from infringing the suit patent held by Bristol Myers.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\">The plaintiff, Bristol Myers is a company incorporated in Ireland. Bristol Myers averred that they were registered owners of the suit patent which covers a molecule having an International Non-proprietary Name (INN) \u201cApixaban\u201d used in the prevention and treatment of thromboembolic diseases. Natco Pharma had filed a petition before the Intellectual Property Appellate Board seeking revocation of the suit patent, which petition is still pending. Bristol Myers brought the present suit because as per its information, Natco Pharma was planning to launch a generic version of Apixaban under the probable brand name \u201cApigat\u201d. Bristol Myers made prayers for a permanent injunction, restraining the Natco Pharma from using, making, selling, storing, distributing, advertising, marketing, exporting, offering for sale, importing or in any other manner directly or indirectly dealing in any product, including but not limited to Apigat that was alleged to infringe the subject matter of the suit patent. Along with the suit, Bristol Myers also filed an application seeking an interim injunction under Order 39 Rules 1 and 2 CPC.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\">Before the Single Judge, Natco Pharma appeared on caveat. The Single Judge, however, passed the order of interim injunction as mentioned above on the lines of an earlier order in <i>Sterlite Technologies Ltd. <\/i>v. <i>ZTT (India) (P) Ltd.<\/i>, CS (Comm) No. 314 of 2019, dt. 31-5-2019. Aggrieved, Natco Pharma filed the present appeal.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\">Sai Deepak, Advocate representing Natco Pharma, contended that the impugned interim order was contrary to the settled law explained in several decisions of the Supreme Court in the matter of granting <i>ad interim<\/i> injunction. Per contra, Senior Advocate Amit Sibal appearing for Bristol Myers supported the order and submitted that it was dishonest on the part of Natco Pharma to risk introducing its product in the market without pursuing its revocation application pending before the IPAB.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\">The High Court referred to a conspectus of judicial precedents where legal principals in relation to orders of interim injunction were enunciated and explained. Reliance was placed on Supreme Court decisions including <i>Wander<\/i> v. <i>Antox<\/i>, <a href=\"http:\/\/scconline.com\/DocumentLink\/EMuaW316\">1990 (Supp) SCC 727<\/a>; <i>Dorab Cawasji Warden<\/i> v. <i>Coomi Sorab Warden<\/i>, <a href=\"http:\/\/scconline.com\/DocumentLink\/uK109Ff0\">(1990) 2 SCC 117<\/a>; <i>Tek Singh<\/i> v. <i>Shashi Verma<\/i>, <a href=\"http:\/\/scconline.com\/DocumentLink\/Rm6HvIja\">2019 SCC OnLine SC 168<\/a>;\u00a0<i>Seema Arshad Zaheer<\/i> v. <i>Municipal Corporation of Greater Mumbai<\/i>, <a href=\"http:\/\/scconline.com\/DocumentLink\/9e4T89W5\">(2006) 5 SCC 282<\/a>; etc. Reliance was further placed upon <i>Mahadeo Savlaram Shelke<\/i> v. <i>Pune Municipal Corporation<\/i>, (1995) 3 SCC 33, where the Supreme Court explained that the expressions \u201cprima facie\u201d case, \u201cbalance of convenience\u201d, \u201cirreparable hardship\u201d were not rhetorical phrases for mere incantation.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\">The High Court was of the view that <i>matters involving alleged infringement of patents constitute a separate species of litigation. A further sub-species would be those concerning pharmaceutical patents<\/i>. This is because the law concerning them under the Patents Act, 1970 and other related legislation has peculiar elements that would have to be kept in view by the Court. On facts of the case, it was noted that there was no formation of an opinion by the Single Judge of the Bristol Myers having made out a <i>prima facie<\/i> case in their favour for grant of an interim injunction. Furthermore, as regards the other two elements, viz., <i>balance of convenience<\/i> and <i>irreparable hardship<\/i>, there was no mention of these, even impliedly in the impugned order.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\">The Court observed: <b>\u201cAlthough, there are special features in litigation involving infringement of patents, that still would not obviate the Court dealing with the question of grant of interim injunction to record the three important elements as have been stressed in a large number of decisions of the Supreme Court. It is not necessary that the order granting or refusing interim injunction should expressly state about the above elements but a reading of the order should indicate the forming of an opinion by the Court on the said aspects\u201d<\/b>. In Court\u2019s opinion, a reading of the impugned order did not reflect that the Single Judge had formed such an opinion on the aforementioned elements. Further: <b>\u201cThe decision in the application of interim injunction has to necessarily indicate the view of the Court on the three elements mentioned hereinbefore and the additional features when it involves a case of alleged infringement of a patent, and in particular, a pharmaceutical patent. It is not the length of the order or its precise wording that matters. It is necessary, however, that the factors mentioned hereinbefore must be discernible from the order which comes to a conclusion one way or the other regarding the grant of an interim injunction\u201d<\/b>. <span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\">In such view of the matter, the Court held that the impugned interim order be set aside and the application for interim injunction be decided afresh by the Single Judge. It was directed that until then, the status quo as on 5-7-2019, prior to the passing of the impugned order shall be maintained. [Natco Pharma Ltd. v. Bristol Myers Squibb Holdings Ireland Unlimited, <a href=\"http:\/\/scconline.com\/DocumentLink\/W31HN2VV\"><b>2019 SCC OnLine Del 9164<\/b><\/a>, decided on 16-07-2019]<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delhi High Court: The Division Bench of Dr S. Muralidhar and Talwant Singh, JJ. allowed the appeal filed by Natco Pharma Ltd. <\/p>\n","protected":false},"author":8808,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3,10],"tags":[14321,36690,36692,36691],"class_list":["post-217059","post","type-post","status-publish","format-standard","hentry","category-casebriefs","category-highcourts","tag-interim-injunction","tag-natco-pharma","tag-non-proprietary-name","tag-paten-suit"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.4 (Yoast SEO v26.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0 | SCC Times<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0\" \/>\n<meta property=\"og:description\" content=\"Delhi High Court: The Division Bench of Dr S. Muralidhar and Talwant Singh, JJ. allowed the appeal filed by Natco Pharma Ltd.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/\" \/>\n<meta property=\"og:site_name\" content=\"SCC Times\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/scc.online\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-19T03:00:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-07-25T10:28:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/10\/Delhi-HC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1329\" \/>\n\t<meta property=\"og:image:height\" content=\"888\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Bhumika Indulia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bhumika Indulia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/\",\"name\":\"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0 | SCC Times\",\"isPartOf\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\"},\"datePublished\":\"2019-07-19T03:00:51+00:00\",\"dateModified\":\"2019-07-25T10:28:07+00:00\",\"author\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.scconline.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\",\"url\":\"https:\/\/www.scconline.com\/blog\/\",\"name\":\"SCC Times\",\"description\":\"Bringing you the Best Analytical Legal News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.scconline.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a\",\"name\":\"Bhumika Indulia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg\",\"contentUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg\",\"caption\":\"Bhumika Indulia\"},\"url\":\"https:\/\/www.scconline.com\/blog\/post\/author\/editor_1\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0 | SCC Times","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/","og_locale":"en_US","og_type":"article","og_title":"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0","og_description":"Delhi High Court: The Division Bench of Dr S. Muralidhar and Talwant Singh, JJ. allowed the appeal filed by Natco Pharma Ltd.","og_url":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/","og_site_name":"SCC Times","article_publisher":"https:\/\/www.facebook.com\/scc.online\/","article_published_time":"2019-07-19T03:00:51+00:00","article_modified_time":"2019-07-25T10:28:07+00:00","og_image":[{"width":1329,"height":888,"url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/10\/Delhi-HC.jpg","type":"image\/jpeg"}],"author":"Bhumika Indulia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Bhumika Indulia","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/","url":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/","name":"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0 | SCC Times","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/#website"},"datePublished":"2019-07-19T03:00:51+00:00","dateModified":"2019-07-25T10:28:07+00:00","author":{"@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a"},"breadcrumb":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.scconline.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.scconline.com\/blog\/#website","url":"https:\/\/www.scconline.com\/blog\/","name":"SCC Times","description":"Bringing you the Best Analytical Legal News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.scconline.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a","name":"Bhumika Indulia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg","contentUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg","caption":"Bhumika Indulia"},"url":"https:\/\/www.scconline.com\/blog\/post\/author\/editor_1\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":296408,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/07\/10\/delhi-hc-denies-interim-injunction-to-bayer-healthcare-for-drug-regorafenib-legal-news\/","url_meta":{"origin":217059,"position":0},"title":"\u2018Public interest demands easy, affordable access to anti-cancer drug\u2019; Delhi High Court denies interim injunction to Bayer Healthcare for drug \u2018Regorafenib\u2019","author":"Simranjeet","date":"July 10, 2023","format":false,"excerpt":"Bayer healthcare LLC was selling its product of Rs. 36,995 by importing the same into India, whereas the Natco Pharma Ltd. was manufacturing the product in India and selling the same of Rs. 9,900. The injunction was refused due to the huge disparity between the prices offered by both, for\u2026","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"delhi high court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":281943,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/01\/19\/delhi-high-court-rules-principles-of-natural-justice-to-be-followed-by-indian-patent-office-in-pre-grant-opposition-stage-novartis-natco-hearing-both-sides-necessary-legalnews-legalresearch-legalupdat\/","url_meta":{"origin":217059,"position":1},"title":"Delhi High Court rules in the context of the procedure and principles of natural justice to be observed by the Indian Patent Office in a pre-grant opposition to a patent application","author":"Editor","date":"January 19, 2023","format":false,"excerpt":"In pharmaceutical patents, especially, additional care must be taken to ensure that, by being allowed to evergreen a patent beyond its expiry, the patent holder does not keep others, who may seek to deal in the patented product, out of the market. The ultimate sufferer, in such a situation, would\u2026","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"Delhi High Court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2022\/12\/MicrosoftTeams-image-418.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":214890,"url":"https:\/\/www.scconline.com\/blog\/post\/2019\/05\/21\/del-hc-ajanta-pharma-injuncted-from-selling-its-nutraceutical-product-glotab-in-passing-off-suit-brought-by-sun-pharma-principles-reiterated\/","url_meta":{"origin":217059,"position":2},"title":"Del HC | Ajanta Pharma injuncted from selling its nutraceutical product GLOTAB in passing off suit brought by Sun Pharma; principles reiterated","author":"Bhumika Indulia","date":"May 21, 2019","format":false,"excerpt":"Delhi High Court:\u00a0Pratibha Singh, J., while allowing the suit brought by Sun Pharma Laboratories Ltd., passed an order injuncting Ajanta Pharma Ltd. from selling any medicinal preparations, nutritional food supplements or any other preparations for human consumption for treating any illnesses or diseases under the trademark GLOTAB or any other\u2026","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":337758,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/12\/23\/delhi-hc-grants-ex-parte-ad-interim-injunction-mankind-pharma-restrain-infringement-trade-mark\/","url_meta":{"origin":217059,"position":3},"title":"Delhi High Court grants ex-parte ad-interim injunction in favour of Mankind Pharma Ltd. to restrain infringement of trade mark","author":"Editor","date":"December 23, 2024","format":false,"excerpt":"It was said that if no ex-parte ad-interim injunction is granted, Mankind Pharma would suffer an irreparable loss.","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"Delhi High Court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Delhi-High-Court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Delhi-High-Court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Delhi-High-Court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Delhi-High-Court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":299984,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/08\/24\/delhi-hc-modifies-patent-injunction-to-extent-honeycomb-panels-are-for-supply-to-ministry-of-defence\/","url_meta":{"origin":217059,"position":4},"title":"Delhi High Court modifies patent injunction to the extent honeycomb panels are for supply to the Ministry of Defence","author":"Simranjeet","date":"August 24, 2023","format":false,"excerpt":"\u201cThe defendant is selling honeycomb panels to the Ministry of Defence since 2012 and containers of the defendant cannot be sold without the panel, considering the purpose for which containers are stated to be needed, that too by the Ministry of Defence.\u201d","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"delhi high court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":325977,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/07\/07\/top-intellectual-property-cases-june-2024-legal-news\/","url_meta":{"origin":217059,"position":5},"title":"Intellectual Property Rights | A quick view of top Intellectual Property cases in June 2024","author":"Editor","date":"July 7, 2024","format":false,"excerpt":"A quick recap of Intellectual Property cases passed by the High Courts in the month of June 2024 along with some top stories on Domino\u2019s, Infosys Trademark Infringement, Patent for Portable Vehicle Management System and much more.","rel":"","context":"In &quot;Legal RoundUp&quot;","block_context":{"text":"Legal RoundUp","link":"https:\/\/www.scconline.com\/blog\/post\/category\/columns-for-roundup\/"},"img":{"alt_text":"Intellectual Property cases Roundup June 2024","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/07\/Intellectual-Property-cases-Roundup-June-2024.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/07\/Intellectual-Property-cases-Roundup-June-2024.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/07\/Intellectual-Property-cases-Roundup-June-2024.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/07\/Intellectual-Property-cases-Roundup-June-2024.webp?resize=700%2C400&ssl=1 2x"},"classes":[]}],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/217059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/users\/8808"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/comments?post=217059"}],"version-history":[{"count":0,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/217059\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media?parent=217059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/categories?post=217059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/tags?post=217059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}